TC Biopharm (NASDAQ:TCBP) & Monte Rosa Therapeutics (NASDAQ:GLUE) Head to Head Contrast

Monte Rosa Therapeutics (NASDAQ:GLUE) and TC Biopharm (NASDAQ:TCBP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Risk and Volatility

Monte Rosa Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, TC Biopharm has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Monte Rosa Therapeutics and TC Biopharm, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	0	1	3	0	2.75
TC Biopharm	0	0	0	0	N/A

Monte Rosa Therapeutics presently has a consensus price target of $12.25, suggesting a potential upside of 201.72%. Given Monte Rosa Therapeutics’ higher possible upside, equities research analysts plainly believe Monte Rosa Therapeutics is more favorable than TC Biopharm.

Valuation and Earnings

This table compares Monte Rosa Therapeutics and TC Biopharm’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	N/A	N/A	-$135.35 million	($2.52)	-1.61
TC Biopharm	$4.76 million	0.86	-$7.35 million	N/A	N/A

TC Biopharm has higher revenue and earnings than Monte Rosa Therapeutics.

Profitability

This table compares Monte Rosa Therapeutics and TC Biopharm’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	N/A	-74.13%	-49.14%
TC Biopharm	N/A	N/A	N/A

Institutional & Insider Ownership

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 16.3% of TC Biopharm shares are held by institutional investors. 6.5% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 15.4% of TC Biopharm shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

TC Biopharm beats Monte Rosa Therapeutics on 5 of the 9 factors compared between the two stocks.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.